Paul Hastings latest transaction was an Uninformative Sell of $3.20K.
What was Paul Hastings's most profitable transaction?
Paul Hastings’s most profitable transaction was an Informative Sell of NKTX stock on January 18, 2024. The return on the trade was 70.90%.
What is Paul Hastings's role in OncoMed Pharma?
Paul Hastings's role in OncoMed Pharma is Chairman & CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.